TY - JOUR
T1 - Barrett esophagus length, nodularity, and low-grade dysplasia are predictive of progression to esophageal adenocarcinoma
AU - Solanky, Dipesh
AU - Krishnamoorthi, Rajesh
AU - Crews, Nicholas
AU - Johnson, Michele
AU - Wang, Kenneth
AU - Wolfsen, Herbert
AU - Fleischer, David
AU - Ramirez, Francisco C.
AU - Katzka, David
AU - Buttar, Navtej
AU - Iyer, Prasad G.
N1 - Funding Information:
Received for publication November 28, 2017; accepted February 12, 2018. From the *Mayo Clinic School of Medicine School; †Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN; ‡Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL; and §Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ. D.S. and R.K. are co-first authors and contributed equally. D.S. and R.K.: drafting of manuscript and data interpretation. P.G.I. and R.K.: study concept and design. R.K. and N.C.: data abstraction and analysis. M.J.: technical support. K.W., H.W., D.F., F.C.R., D.K., N.B., and P.G.I.: critical review of manuscript. P.G.I. supported by research grants from Exact Sciences, C2 Ther-apeutics, and Medtronic. The authors declare that they have nothing to disclose. Address correspondence to: Prasad G. Iyer, MSc, MD, FASGE, Barrett’s Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester 55905, MN (e-mail: iyer.prasad@mayo.edu). Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/MCG.0000000000001027
Publisher Copyright:
Copyright © 2019 World Gastroenterology Organisation. All rights reserved.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Goals: To investigate factors predictive of progression from nondysplastic Barrett esophagus (NDBE) or low-grade dysplasia (LGD) to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) using a large, prospective cohort of patients, wherein all esophageal biopsies undergo expert gastrointestinal pathologist review. Background: Efficacy and cost-effectiveness of endoscopic surveillance to detect incident EAC in the setting of Barrett esophagus (BE), particularly in NDBE patients, is questioned. Previous studies have reported factors predictive of progression to EAC to guide surveillance intervals, but their strength is limited by small sample size and absence of expert gastrointestinal pathologist involvement in esophageal biopsy review. Study: NDBE and LGD subjects were identified from a prospective registry in a tertiary care center. "Progressors" were BE subjects who developed HGD/EAC>12 months after the initial NDBE or LGD diagnosis. Cox proportional hazards model were used to identify predictors of progression. Results: In total, 318 with NDBE and 301 with BE-LGD (mean age, 62.6 y, 85% male) were included. The mean follow-up was 5.3 years. The 7 NDBE and 21 LGD subjects progressed to HGD/EAC. BE length [hazards ratio (HR), 1.16; 95% confidence interval (CI), 1.03- 1.29], presence of nodularity (HR, 4.98; 95% CI, 1.80-11.7), and baseline LGD (HR, 2.57; 95% CI, 1.13-6.57) were significant predictors of progression on multivariate analysis. Conclusions: In this well-defined cohort of NDBE and BE-LGD subjects, BE length, presence of LGD, and nodularity were independent predictors of progression to HGD/EAC. These factors may aid in identifying high-risk patients who may benefit from closer endoscopic surveillance/therapy.
AB - Goals: To investigate factors predictive of progression from nondysplastic Barrett esophagus (NDBE) or low-grade dysplasia (LGD) to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) using a large, prospective cohort of patients, wherein all esophageal biopsies undergo expert gastrointestinal pathologist review. Background: Efficacy and cost-effectiveness of endoscopic surveillance to detect incident EAC in the setting of Barrett esophagus (BE), particularly in NDBE patients, is questioned. Previous studies have reported factors predictive of progression to EAC to guide surveillance intervals, but their strength is limited by small sample size and absence of expert gastrointestinal pathologist involvement in esophageal biopsy review. Study: NDBE and LGD subjects were identified from a prospective registry in a tertiary care center. "Progressors" were BE subjects who developed HGD/EAC>12 months after the initial NDBE or LGD diagnosis. Cox proportional hazards model were used to identify predictors of progression. Results: In total, 318 with NDBE and 301 with BE-LGD (mean age, 62.6 y, 85% male) were included. The mean follow-up was 5.3 years. The 7 NDBE and 21 LGD subjects progressed to HGD/EAC. BE length [hazards ratio (HR), 1.16; 95% confidence interval (CI), 1.03- 1.29], presence of nodularity (HR, 4.98; 95% CI, 1.80-11.7), and baseline LGD (HR, 2.57; 95% CI, 1.13-6.57) were significant predictors of progression on multivariate analysis. Conclusions: In this well-defined cohort of NDBE and BE-LGD subjects, BE length, presence of LGD, and nodularity were independent predictors of progression to HGD/EAC. These factors may aid in identifying high-risk patients who may benefit from closer endoscopic surveillance/therapy.
KW - Barrett esophagus
KW - Esophageal adenocarcinoma
KW - Low-grade dysplasia
KW - No dysplasia
KW - Predictors of progression
UR - http://www.scopus.com/inward/record.url?scp=85053841044&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053841044&partnerID=8YFLogxK
U2 - 10.1097/MCG.0000000000001027
DO - 10.1097/MCG.0000000000001027
M3 - Article
C2 - 29608452
AN - SCOPUS:85053841044
SN - 0192-0790
VL - 53
SP - 361
EP - 365
JO - Journal of clinical gastroenterology
JF - Journal of clinical gastroenterology
IS - 5
ER -